ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration https://archerdx.com/archerdx-and-ayala-pharmaceuticals-announce-strategic-companion-diagnostic-collaboration/

ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration Enabling Genomically Defined Treatments for Underserved Cancers BOULDER, Colo., July 8, 2019 /PRNewswire/ — ArcherDX, Inc., […]
ArcherDX, Inc. Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio https://archerdx.com/archerdx-inc-announces-close-of-60m-financing-to-advance-companion-diagnostic-and-minimal-residual-disease-monitoring-product-portfolio-2/

ArcherDX, Inc. Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio BOULDER, Colo., May, 15, 2019 /PRNEWSWIRE/– ArcherDX, […]
ArcherDX, Inc. Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio https://archerdx.com/archerdx-inc-announces-close-of-60m-financing-to-advance-companion-diagnostic-and-minimal-residual-disease-monitoring-product-portfolio/

ArcherDX, Inc. Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio BOULDER, Colo., May, 15, 2019 /PRNEWSWIRE/– ArcherDX, […]
ArcherDX, Inc. Announces the Appointment of Steven J. Kafka, Ph.D. as Executive Chairman of the Board of Directors https://archerdx.com/archerdx-inc-announces-the-appointment-of-steven-j-kafka-ph-d-as-executive-chairman-of-the-board-of-directors/

ArcherDX, Inc. Announces the Appointment of Steven J. Kafka, Ph.D. as Executive Chairman of the Board of Directors BOULDER, Colo., May, 29, 2019 /PRNEWSWIRE/– ArcherDX, […]
ArcherDX announces collaboration with University College London to Investigate the Novel Use of Cell-Free Circulating Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients https://archerdx.com/archerdx-announces-collaboration-with-university-college-london-to-investigate-the-novel-use-of-cell-free-circulating-tumor-dna-to-detect-disease-recurrence-in-lung-cancer-patients/

ArcherDX announces collaboration with University College London to Investigate the Novel Use of Cell-Free Circulating Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients […]
ArcherDX, Inc. Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth https://archerdx.com/archerdx-inc-announces-expansion-of-executive-leadership-team-as-company-continues-to-experience-rapid-growth/

ArcherDX, Inc. Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth BOULDER, Colo., March 5, 2019 — ArcherDX, Inc., a molecular […]
ArcherDX, Inc. Announces Broad-Based Strategic Collaboration with Genosity https://archerdx.com/archerdx-inc-announces-broad-based-strategic-collaboration-with-genosity/

ArcherDX, Inc. Announces Broad-Based Strategic Collaboration with Genosity February 12, 2019 BOULDER, CO-ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance […]
ArcherDX, Inc. Acquires Baby Genes, a Genetics-Based Personalized Medicine Company https://archerdx.com/archerdx-inc-acquires-baby-genes-a-genetics-based-personalized-medicine-company/

ArcherDX, Inc. Acquires Baby Genes, a Genetics-Based Personalized Medicine Company January 30, 2019 BOULDER, CO-ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions […]
ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests https://archerdx.com/archerdx-and-illumina-partner-for-future-to-co-market-portfolio-of-planned-in-vitro-diagnostic-ivd-tests/

ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests Co-marketing partnership to drive awareness of ArcherDX IVD products and […]
ArcherDX’s Companion Diagnostic Test for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration https://archerdx.com/archerdxs-companion-diagnostic-test-for-both-liquid-biopsy-and-tissue-specimens-granted-breakthrough-device-designation-by-u-s-food-and-drug-administration/

ArcherDX’s Companion Diagnostic Test for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration January 8, 2019 BOULDER, […]